Increased frequency of TP53 mutations in BRCAI and BRCA2 ovarian tumours

Genes Chromosomes and Cancer

Volumn 25, Issue 2, 1999, Pages 91-96

  Ramus, Susan J ^a   Bobrow, Lynda G ^b   Pharoah, Paul D P ^a   Finnigan, Damon S ^a   Fishman, Ami ^c   Altaras, Marco ^c   Harrington, Patricia A ^a   Gayther, Simon A ^a   Ponder, Bruce A J ^a   Friedman, Lori S ^a,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c MEIR MEDICAL CENTER   (Israel)

^d EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CORRELATION FUNCTION; DNA DETERMINATION; DNA REPAIR; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; OVARY TUMOR; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

ALLELES; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032960931     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199906)25:2<91::AID-GCC3>3.0.CO;2-5     Document Type: Article

References (32)

1. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. 1998. Minireview: the TP53 network. J Biol Chem 273:1-4.
2. Avigad S, Barel D, Blau O, Malka A, Zoldan M, Mor C, Fogel M, Cohen IJ, Stark B, Goshen Y, Stein J, Zaizov R. 1997. A novel germ line mutation in intron 6 in diverse childhood malignancies. Oncogene 14:1541-1545.
3. Bertwisle D, Ashworth A. 1998. Functions of the BRCA1 and BRCA2 genes. Curr Opin Genet Dev 8:14-20.
4. Brugarolas J, Jacks T 1997. Double indemnity: TP53, BRCA and cancer. Nat Med 3:721-722.
5. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ 1996. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known TP53 alterations in human malignancies. Oncogene 13:1971-1981.
6. Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, Tybulewicz VLJ, Ashworth A. 1997. Tumorigenesis and a DNA repair defect in mice with truncated BRCA2. Nat Genet 17:423-430.
7. Craanen ME, Blok P, Dekker W, Offerhaus GJA, Tytgat GNJ. 1995. Chronology of TP53 protein acumualation in gastric carcinogenesis. Gut 36:848-852.
8. Crook T, Crossland S, Crompton M, Osin P, Gusterson B. 1997. TP53 mutations in BRCA-associated familial breast cancer. Lancet 350:638-639.
9. Easton D. 1997. Breast cancer genes - What are the real risks? Nat Genet 16:210-211.
10. Eiriksdottir G, Barkardottir RB, Agnarsson BA, Johannesdottir G, Olasdottir K, Egilsson V, Ivgvarsson S. 1998. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers. Oncogene 16:21-26.
11. Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR, Blumenson LE. 1997. TP53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Canter 80:892-898.
12. Foster K, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott IV, Jacobs I, Chenevix-Trench G, Ponder BAJ, Gayther SA. 1996. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 56:3622-3625.
13. Friedman LS, Thistlewaite FC, Patel KY, Yu VPCC, Lee H, Venkitaraman AR, Abel KJ, Calton MBL, Hunter SM, Colledge WH, Evans MJ, Ponder BAJ. 1998. Thymic lymphomas in mice with a truncating mutation in BRCA2. Cancer Res 58:1338-1343.
14. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM, Love R, Evans G, Easton D, Clayton D, Stratton MR, Ponder BAJ. 1995. Germline mutations of the BRCA1 gene in breast and ovarian-cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11:428-433.
15. Gretarsdottir S, Thorlacius S, Valgardsdottir R, Gudlaugsdottir S, Sigurdsson S, Steinarsdottir M, Gunnlaugur JJ, Anamthawat-Jonsson K, Eyfjord JE. 1998. BRCA2 and TP53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 58:859-862.
16. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J. 1997. Single-step DGGE-based mutation scanning of the TP53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat 9:348-355.
17. Hakem R, de la Pompa JL, Elia A, Potter J, Mak TW. 1997. Rescue of BRCA1 early embryonic lethality by TP53 or p21 null mutation. Nat Genet 16:298-302.
18. Hartmann A, Blaszyk H, McGovern RM, Schroeder JJ, Cunningham J, De Vries EMG, Kovach JS, Sommer SS. 1995. TP53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 10:681-688.
19. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA, Roche PC. 1994. Prognostic significance of TP53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12:64-69.
20. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC. 1996. Somatic point mutations in the TP53 gene of human tumours and cell lines: updated compilation. Nucleic Acids Res 24:141-146.
21. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H. 1995. TP53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76:1201-1208.
22. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW. 1993. TP53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90:4961-4965.
23. Levine AJ. 1997. TP53, the cellular gatekeeper for growth and division. Cell 88:323-331.
24. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. 1997. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of BRCA1 BRCA2 BRCA1/BRCA2 BRCA1/TP53 and BRCA2/TP53 nullizygous embryos. Genes Dev 11:1226-1241.
25. McManus DT, Yap EPH, Maxwell P, Russell SEH, Toner PG, McGee JO'D. 1994. TP53 expression mutation and allelic deletion in ovarian cancer. J Pathol 174:159-168.
26. Patel KJ, Yu VPCC, Lee H, Corcoran A, Thistlewaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BAJ, Venkitaraman AR. 1998. Involvement of BRCA2 in DNA repair. Mol Cell 1:347-357.
27. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A. 1997. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 386:804-810.
28. Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, Easton D, Ponder BAJ. 1997. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 336:1125-1130.
29. Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R, Nishina H, Chuang T, Wakeham A, Itie A, Koo W, Billia P, Ho A, Fukumoto M, Hui CC, Mak TW. 1997. BRCA2 is required for embryonic cellular proliferation in the mouse. Genes Dev 11:1242-1252.
30. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A, Kallioniemi OP. 1997. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57:1222-1227.
31. Wong C, DiCioccio RA, Allen HJ, Werness BA, Piver S. 1998. Mutations in BRCA1 from fixed paraffin embedded tissue can be artifacts of preservation. Cancer Genet Cytogenet (in press).
32. Zhang H, Somasundarum K, Peng Y, Tian H, Zhang H, Di D, Weber BL, El-Deiry WS. 1998. BRCA1 physically associates with TP53 and stimulates its transcriptional activity. Oncogene 16:1713-1721.